Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

Inclusion Criteria Concurrent Medication: Allowed: * Zidovudine (AZT). * All drugs used for the standard treatment of opportunistic infections. * Other drugs used for the treatment of other AIDS conditions if they have been started more than 3 months prior to study entry. Patients must have: * Diagnosis of AIDS. * Weight loss of \> 10 percent premorbid body weight. * Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma. * Require home total parenteral nutrition (TPN) for a period of approximately 3 months. * Life expectancy = or \> 90 days. Prior Medication: Allowed: * Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Life expectancy \< 90 days. * Biliary stasis. * History of drug abuse. Patients with the following are excluded: * Life expectancy \< 90 days. * Biliary stasis. * History of drug abuse. Prior Medication: Excluded within 3 months of study entry: * Immunomodulators. * Experimental antiviral DT. History of drug abuse.